M

    MaxCyte Inc (MXCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.29
    +0.07 (+5.74%)

    Market Cap: $125.91M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(19/22)
    Avg Surprise
    +16.09%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.09 - $-0.08
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.08+7.9%
    60d ago$-0.08+7.9%
    30d ago$-0.07+10.0%
    7d ago$-0.08+4.0%
    Current$-0.08
    Revenue Consensus
    $7M
    Range$6M - $7M
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.00
    Range$-0.03 - $0.02
    4 analysts
    Revenue Consensus
    $11M
    Range$10M - $11M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.00---
    Sep 26EST
    		-$-0.08---
    Jun 26
    		$-0.08$-0.12+33.33%Beat+33.3%
    Mar 26
    		$-0.04$-0.07+31.69%Beat+55.6%
    Dec 25
    		$-0.06$-0.08+25.00%Beat+40.0%
    Sep 25
    		$-0.09$-0.10+10.00%Beat+18.2%
    Jun 25
    		$-0.12$-0.10-20.00%Miss-33.3%
    Mar 25
    		$-0.10$-0.10+0.00%Beat-11.1%
    Dec 24
    		$-0.10$-0.12+16.67%Beat-100.0%
    Sep 24
    		$-0.11$-0.12+8.33%Beat+0.0%
    Jun 24
    		$-0.09$-0.13+30.77%Beat+10.0%
    Mar 24
    		$-0.09$-0.13+30.77%Beat+18.2%
    Dec 23
    		$-0.05$-0.07+28.57%Beat+0.0%
    Sep 23
    		$-0.11$-0.10-10.00%Miss-83.3%
    Jun 23
    		$-0.10$-0.10+0.00%Beat-25.0%
    Mar 23
    		$-0.11$-0.11+0.00%Beat-175.0%
    Dec 22
    		$-0.05$-0.07+28.57%Beat+0.0%
    Sep 22
    		$-0.06$-0.08+25.00%Beat-100.0%
    Jun 22
    		$-0.08$-0.07-14.29%Miss-60.0%
    Mar 22
    		$-0.04$-0.07+42.86%Beat+42.9%
    Dec 21
    		$-0.05$-0.05+0.00%Beat+43.0%
    Sep 21
    		$-0.03$-0.05+40.00%Beat+19.4%
    Jun 21
    		$-0.05$-0.06+16.67%Beat-34.4%
    Mar 21
    		$-0.07$-0.10+30.00%Beat-31.3%
    Dec 20
    		$-0.09$0.00N/AMiss-194.3%
    Sep 20
    		$-0.04$0.00N/AMiss-24.8%
    Jun 20
    		$-0.04$0.00N/AMiss+56.5%
    Dec 19
    		$-0.05$0.00N/AMiss+37.7%
    Sep 19
    		$-0.03$0.00N/AMiss+25.1%
    Jun 19
    		$-0.03$0.00N/AMiss+25.1%
    Mar 19
    		$-0.09$0.00N/AMiss-82.3%
    Dec 18
    		$-0.09$0.00N/AMiss-82.3%
    Sep 18
    		$-0.04$0.00N/AMiss+27.9%
    Jun 18
    		$-0.04$0.00N/AMiss+27.9%
    Mar 18
    		$-0.05$0.00N/AMiss-1.3%
    Dec 17
    		$-0.05$0.00N/AMiss-1.3%
    Sep 17
    		$-0.06$0.00N/AMiss-131.9%
    Jun 17
    		$-0.06$0.00N/AMiss-
    Mar 17
    		$-0.05$0.00N/AMiss-
    Dec 16
    		$-0.05$0.00N/AMiss-
    Sep 16
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.70EV/EBITDA-11.07x
    Price/FCF-5.83xFCF Yield-17.16%
    Profitability
    Profit Margin-114.80%Operating Margin-140.70%
    ROE-20.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio12.26xQuick Ratio11.47x
    Trading Statistics
    Beta1.49Avg Volume810.31K
    52-Week High$1.8652-Week Low$0.64

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.33
    SMA 20$1.27
    SMA 50$1.23
    SMA 200$1.13
    EMA 10$1.30
    EMA 20$1.28
    EMA 50$1.22
    EMA 200$1.26

    MACD

    Line: 0.03Signal: 0.04Hist: -0.01

    ADX

    ADX: 33.3+DI: 21.8-DI: 19.1

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down4.0
    PSAR$1.49

    Bollinger Bands

    Upper Band$1.47
    Lower Band$1.08
    %B Position3114%(Upper)
    Band Width0.54

    RSI (14-Day)

    Neutral
    52.5

    Momentum Oscillators

    Stoch %K27.2
    Stoch %D34.4
    Williams %R-65.8
    ROC (10d)-2.3%
    Momentum-0.03
    CCI (20d)-7.0
    MFI (14d)73.8

    Volatility Measures

    ATR (14d)$0.09(6.6%)
    StdDev (20d)0.10
    Hist Vol70.5%(High)

    Volume Flow

    VWAP$1.26
    OBV-17.5M
    AD Line-28.0M
    CMF (20d)0.032

    Volume Metrics

    Avg Vol (20d)832.1K
    Vol Ratio0.9x
    VWMA (20d)$1.30

    Pivot Points

    R3$1.37
    R2$1.33
    R1$1.28
    Pivot Point$1.24
    S1$1.19
    S2$1.15
    S3$1.10

    Advanced Oscillators

    TSI10.79
    Ultimate Osc44.7
    KST132.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.27M$9.65M$7.30M$6.83M$8.51M$10.39M$8.69M$8.16M$10.43M$11.34M$15.66M$8.00M
    Cost of Revenue$1.68M$1.57M$1.61M$1.60M$1.52M$1.50M$2.28M$1.93M$1.49M$1.40M$1.57M$793,000
    Gross Profit$5.60M$8.08M$5.69M$5.23M$6.99M$8.89M$6.41M$6.24M$8.94M$9.94M$14.09M$7.21M
    Operating Expenses$15.83M$14.27M$16.92M$19.38M$21.21M$21.19M$19.31M$20.29M$20.91M$22.21M$22.19M$21.16M
    R&D$4.25M$3.86M$3.33M$5.32M$6.27M$5.90M$4.61M$5.32M$5.62M$6.68M$5.84M$6.26M
    SG&A$7.26M$5.97M$5.48M$6.03M$8.08M$8.53M$7.21M$7.75M$7.64M$7.10M$8.09M$6.82M
    Operating Income$-10,232,000$-6,185,000$-11,226,000$-14,149,000$-14,227,000$-12,295,000$-12,901,000$-14,053,000$-11,968,000$-12,275,000$-8,096,000$-13,952,000
    Interest Income$1.36M$1.44M$1.63M$1.73M$1.87M$2.03M$2.30M$2.50M$2.59M$2.75M$2.82M$2.70M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-8,874,000$-4,750,000$-9,596,000$-12,416,000$-12,357,000$-10,261,000$-10,597,000$-11,557,000$-9,375,000$-9,526,000$-5,278,000$-11,251,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,874,000$-4,750,000$-9,596,000$-12,416,000$-12,357,000$-10,261,000$-10,597,000$-11,557,000$-9,375,000$-9,526,000$-5,278,000$-11,251,000
    EBITDA$-9,428,000$-5,354,000$-10,366,000$-13,452,000$-13,681,000$-11,902,000$-12,912,000$-14,021,000$-12,685,000$-13,031,000$-8,596,000$-14,353,000
    EBIT$-10,232,000$-6,185,000$-11,226,000$-14,149,000$-14,227,000$-12,295,000$-12,901,000$-14,053,000$-11,968,000$-12,275,000$-8,096,000$-13,952,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MXCT

    Government Contracts

    Gov Obligations (TTM)
    $181450
    Gov Obligations / Revenue
    0.6%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    2
    Avg Remaining Term
    N/A

    Top agency: Department of Health and Human Services at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75N98026P00164Department of Health and Human ServicesNational Institutes of Health$126250Mar 24, 2026
    75N92025P00397Department of Health and Human ServicesNational Institutes of Health$55200Sep 26, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    MaxCyte stock rating held at Neutral by BTIG after Q2 results

    BTIG has reiterated a Neutral rating on MaxCyte Inc. following its Q2 2026 earnings report, where the company slightly beat consensus and reaffirmed its revenue outlook. MaxCyte, despite an 11% year-to-date decline, saw a 75% gain in shares over the last six months and recently signed a multi-platform technology license deal with Genentech. The company expects a return to revenue growth in the second half of 2026, though core revenue is still declining year-over-year.

    Investing.com•8/24/26•
    Neutral

    MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks

    MaxCyte (NASDAQ: MXCT), a cell-engineering company, has reiterated its 2026 revenue guidance of $30-$32 million, driven by high-margin consumables and Strategic Platform License (SPL) milestones. The company recently secured a multi-platform technology license partnership with Genentech, boosting its credibility and potential for enterprise deals. Despite this positive development, MaxCyte continues to face challenges such as lumpy SPL revenue, ongoing operating losses, and high stock volatility.

    Finimize•8/20/26•
    Neutral

    MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

    MaxCyte, Inc. has introduced CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays through its SeQure™ service. These new assays provide sensitive and orthogonal methods for assessing off-target risks in adenine and cytosine base editors, addressing a critical need in genome editing therapy development. The combined approach aims to help therapeutic developers build stronger data packages for clinical development, aligning with evolving regulatory expectations, including recent FDA guidance.

    The Manila Times•8/19/26•
    Bullish

    MaxCyte launches base editor off-target nomination assays

    MaxCyte Inc. (NASDAQ:MXCT) has introduced two new off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, for base editors through its SeQure service. These assays are designed to help therapeutic developers identify and prioritize off-target sites, aligning with regulatory guidance like that from the FDA on genome editing safety. The company aims to provide sensitive and orthogonal assessment capabilities to mitigate off-target risks in clinical development.

    Investing.com•8/19/26•
    Bullish

    MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

    MaxCyte has introduced CHANGE-seq-BE™ and ONE-seq-BE™ assays through its SeQure™ service to enhance off-target assessment for genome editing therapies, specifically for adenine and cytosine base editors. These new assays provide sensitive nomination of off-target sites, addressing a critical gap in genome editing characterization. By offering orthogonal methods, MaxCyte aims to help therapeutic developers confidently assess and mitigate off-target risks, aligning with evolving regulatory expectations.

    The Manila Times•8/19/26•
    Bullish

    Frequently Asked Questions About MXCT

    Does MXCT pay dividends?
    MaxCyte Inc (MXCT) does not currently pay a regular dividend.
    What is MXCT's market cap?
    MaxCyte Inc (MXCT) has a market capitalization of $125.91M with a current stock price of $1.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In